Ê×Ò³| Â鶹´«Ã½Ó³»­

Alzheimer’s patients and their loved ones have a renewed sense of hope now that the U.S. Food & Drug Administration approved the first Alzheimer’s drug in nearly two decades.

The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen.

Now that the FDA has approved Biogen's aducanumab (Aduhelm), the controversial new drug for Alzheimer's disease, what does this mean?

In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.

The Food and Drug Administration (FDA) approved Biogen's aducanumab on June 7, making it the first Alzheimer's medication available in nearly 20 years and the only one that could slow the progression of the disease.

For the first time in nearly 20 years, the FDA approved a drug for the treatment of Alzheimer's disease.

Telephones were ringing off the hook Monday at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, with patients calling to inquire about the U.S. Food and Drug Administration’s approval of a drug designed to slow the progression of Alzheimer’s disease.

For the first time, the US FDA has approved a drug that is supposed to counteract a cause of Alzheimer's disease. But it is highly controversial.